Full Press Release Details
• NeOnc Technologies Holdings is a micro-cap biotech focused on innovative brain cancer treatments, NEO100 and NEO212, both in early clinical trials.
• NTHI’s financials are challenging, with no revenue, rising R&D expenses, and a significant cash burn, but a $50M Quazar partnership is set to transform its outlook.
• The Quazar deal will provide crucial funding, pay off debts, and enable NTHI to accelerate clinical development and expansion in the MENA region.
NeOnc Technologies Holdings, Inc. (NASDAQ: NASDAQ: NTHI ) is a micro-cap biotech company developing new cancer treatments, and while it operates in a crowded field dominated by large pharmaceutical firms, NeOnc focuses on early-stage programs where small, agile teams can still make a meaningful impact. There isn’t much analyst coverage or market attention yet, and I think that’s actually part of the opportunity.
NeOnc Technologies is still a pre-commercial biotech company, meaning it doesn’t make any money yet from selling drugs. Its potential future income would come from two experimental cancer treatments , NEO100 and NEO212, both designed to fight brain tumors. NEO100 is a purified form of a compound called perillyl alcohol (POH) that’s delivered through the nose, allowing it to bypass the blood–brain barrier and target gliomas and other central nervous system (CNS) tumors, while NEO212 combines perillyl alcohol (POH) with temozolomide, it’s a standard chemotherapy used for glioblastoma. The goal is to help the drug reach the brain more efficiently and work against tumors that no longer respond to standard treatments. Both NEO100 and NEO212 are currently in Phase I/II clinical trials, operating under FDA Investigational New Drug (IND) approvals and holding Fast Track designation.
My research here suggests that NeOnc is at a key inflection point from a survival story to a growth story. An upcoming Quazar partnership could significantly improve its financial position, giving the company the runway it needs to advance its brain cancer drug candidates, which have long been starved by a lack of funding.
All things considered, I’d rate NTHI a buy . From a valuation point of view, I still think the best way to look at NeOnc is by comparing its EV to how much money has already been invested. Before this latest news, I was worried about dilution and whether the company could even survive. Now, with the expected new funding, it basically resets the company’s risk premium.
If (when) the deal closes on time, NeOnc’s EV should trade slightly higher than its total invested capital since it would now have a stronger cash position and reliable partners like Quazar and Cleveland Clinic Abu Dhabi backing it up. There’s still some risk until the money actually arrives, but it’s no longer a question of survival in my opinion; it’s about how well they can execute from here.
Click HERE to read the full article from Grassroots Trading.